2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 517

Evaluation of the Effectiveness of Injectable Methotrexate for the Treatment of Rheumatoid Arthritis
Abstract Number: 1441

Evaluation of Ultrasound-Detecting Efficacy of Abatacept By Profiling Multiple Serum Cytokines, Chemokines and Bone-Related Biomarkers in Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort Study
Abstract Number: 1248

Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Abstract Number: 2956

Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Abstract Number: 2330

Evidence for Alternatively Activated (M2) Macrophage Activation in Patients with Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis
Abstract Number: 902

Evidence for Inhibition of Osteoclastogenesis By Cytomegalovirus Infection: Implication in RA Bone Erosion and Identification of a Cellular Protein As a Therapeutic Target
Abstract Number: 2070

Evidence-Based Development of Criteria for Complete Response in Patients with Chronic Refractory Gout
Abstract Number: 1965

Evolution of Anti-Citrullinated Protein Antibodies in Post-Chikungunya Arthritis Patient in Dominican Republic
Abstract Number: 1056

Evolution of Health Care Consumption in the Knee and Hip Osteoarthritis Long Term Assessment Cohort, a French Population Based Cohort of Symptomatic Knee and/or Hip OA Patients
Abstract Number: 2870

Ex Vivo Comparison of Baricitinib, Upadacitinib, Filgotinib, and Tofacitinib for Cytokine Signaling in Human Leukocyte Subpopulations
Abstract Number: 295

Ex Vivo Induced Neutrophil Extracellular Traps Are Intrinsically Different in Anca-Associated Vasculitis and Systemic Lupus Erythematosus
Abstract Number: 70

Excessive Cyclic Compressive Stress Increases Susceptibility to IL-1 in 3D-Cultured Chondrocytes
Abstract Number: 1853

Exercise and Adherence over Two Years: Beliefs of Adults with Knee Osteoarthritis
Abstract Number: 1987

Exercise in Fibromyalgia Patients
Abstract Number: 1568

Existence of IL-6 and IL-17 Mediated Inflammation Amplifier Loop in Reactive Arthritis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].